ADmit Therapeutics Analysis
What is ADmit Therapeutics?
Early diagnostic test for Alzheimer's disease
Employees
1-10
Founded
2017
Industry
Biotechnology
Startup Tag
Yes
Product Features & Capabilities
- MAP-AD test utilizing mitochondrial DNA biomarkers
- Next Generation Sequencing for accurate diagnostics
- Machine Learning techniques for predictive analysis
- Neuropsychological assessments linked to disease progression
- Proprietary methodology for early Alzheimer's detection.
Use Cases
Predict progression from Mild Cognitive Impairment to Alzheimer's Disease; Identify patients for clinical trials based on early biomarkers; Enhance early intervention strategies for Alzheimer's patients; Monitor cognitive changes linked to mitochondrial dysfunction; Support personalized medicine approaches in neurodegenerative disease management.
Other Considerations
Received funding from the European Union’s H2020 program; First Spanish laboratory accredited by the College of American Pathologists; ISO 13485 certified for quality management in medical devices.
4 Yfn Page Information
- Information: ADmit Therapeutics S.L.: more company information coming soon.
- Interests: Not specified.
- Location: Hall 8.1 - 4YFN Stand 8.1A40
- Tagged as startup: Yes
- LinkedIn: Not available
- Twitter: Not available
- Phone Number: Not available
- Email: Not available
- Growth Stage: Not specified
- Country: Not specified
- Founding Year: Not specified
- Company Name: ADmit Therapeutics
- Company Website: https://www.admit-therapeutics.com/en
See something that needs updating? Suggest edits to this profile.
